Introduction: Cariprazine is an orally active and potent D 3 and D 2 partial agonist with preferential binding to D 3 receptors in development for the treatment of schizophrenia and bipolar mania. This study (NCT00694707) evaluated the efficacy and safety of cariprazine in patients with acute exacerbation of schizophrenia. Methods: This study was a multinational, double-blind, randomized, placebo-and active-controlled, fixed-dose trial. Patients were randomized to receive placebo, cariprazine 1.5 mg/d, cariprazine 3.0 mg/d, cariprazine 4.5 mg/d, or risperidone 4.0 mg/d (for assay sensitivity) for 6 weeks of double-blind treatment and 2 weeks of safety follow-up. Primary and secondary efficacy parameters were change from baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) total and Global Impressions-Severity of Illness (CGI-S) scores, respectively. Safety parameters included adverse events (AEs), vital signs, laboratory measures, and extrapyramidal symptom (EPS) scales. Results: Of 732 randomized patients, 64% completed the study. PANSS total score improvement at Week 6 was statistically significant versus placebo for cariprazine 1. The most frequent cariprazine AEs (≥5% and at least twice the rate of the placebo group) were insomnia, extrapyramidal disorder, akathisia, sedation, nausea, dizziness, and constipation. Mean changes in metabolic parameters were small and similar between groups. Conclusion: The results of this study support the efficacy and safety of cariprazine in patients with acute exacerbation of schizophrenia.
Introduction
Schizophrenia is a multidimensional disorder with a heterogeneous patient population that varies considerably in symptomatology, course of illness, severity of disease, and associated medical and psychiatric comorbidities (Tandon et al., 2009) . While antipsychotic medications are the cornerstone of schizophrenia treatment, effectiveness is limited by unfavorable side effects, nonresponse to medication, and modest efficacy on negative symptoms (Kirkpatrick et al., 2006) and cognitive impairment (Buchanan et al., 2005; Keefe et al., 2007) . The Clinical Antipsychotics Trials of Intervention Effectiveness (CATIE) schizophrenia study reported a 64-84% discontinuation rate with various antipsychotic treatments Stroup et al., 2006) . While patients may not adequately respond or tolerate initial treatment, they may respond to a different antipsychotic, suggesting that there may be underlying factors that influence individual outcomes with specific antipsychotic medications (Clark et al., 2011) . Optimal management of schizophrenia predicates the need for new compounds with broader efficacy and better safety profiles.
Although blockade of dopamine D 2 receptors (either by a full antagonist or partial agonist) is believed to be a necessary pharmacologic property shared by all antipsychotics (Nord and Farde, 2011) , affinity for other neuroreceptors varies among available agents. These pharmacological differences may help explain the variation in efficacy Schizophrenia Research 152 (2014) [450] [451] [452] [453] [454] [455] [456] [457] and tolerability observed across individual patients. The dopamine D 3 receptor has emerged as an additional target for antipsychotic drug treatment. High affinity at the D 3 receptor in combination with high D 2 receptor affinity may offer the potential for augmented effect on the cognitive deficits and negative symptoms of schizophrenia (Joyce and Millan, 2005; Laszy et al., 2005; Gyertyán et al., 2008; Kiss et al., 2008) .
Cariprazine is an orally active and potent dopamine D 3 and D 2 receptor partial agonist with preferential binding to D 3 receptors. In vitro, cariprazine has almost 10-fold greater affinity for D 3 than D 2 receptors (Kiss et al., 2010) . Cariprazine showed high and balanced occupancy of both D 3 and D 2 receptors in rat brain in vivo at antipsychotic-like effective doses whereas other antipsychotics demonstrated high occupancy at D 2 and low or no occupancy at D 3 receptors (Kiss et al., 2012) . Cariprazine has 2 major metabolites, desmethyl cariprazine and didesmethyl cariprazine (Citrome, 2013) , which have similar pharmacological activity as the parent compound (data on file).
Cariprazine can be administered with or without food and is well absorbed with peak plasma concentrations in 3-4 h (Citrome, 2013) . Elimination of cariprazine and its 2 major active metabolites is mainly by hepatic metabolism via CYP3A4 (Citrome, 2013) . Cariprazine and its active metabolites show dose-proportional kinetics over the therapeutic dose range (Citrome, 2013) . At steady state, didesmethyl cariprazine is the prominent moiety, with exposure (AUC) about 3-fold higher than cariprazine (data on file). Steady-state exposure of desmethyl cariprazine is about 30 to 40% of cariprazine (Citrome, 2013) . Steady state is reached in about 1 week for cariprazine and desmethyl cariprazine (Citrome, 2013) and 4 weeks for didesmethyl cariprazine (data on file). Upon dosing discontinuation, about 50% reduction in plasma exposure of total active moieties occurs in about 1 week (data on file).
This Phase IIb trial (NCT00694707) was designed to explore the dose range of cariprazine in the treatment of patients with acute exacerbation of schizophrenia.
Methods

Study design
A 9-week, multinational, randomized, double-blind, placebo-and active-controlled, parallel-group, fixed-dose study was conducted from June 2008 to August 2009 in patients with acute exacerbation of schizophrenia. Patients were screened at 65 study centers in the United States, India, Russia, Ukraine, and Malaysia. The study was conducted in compliance with the ICH-E6 Good Clinical Practice guidelines.
After a washout period of up to 7 days, patients were randomized (1:1:1:1:1) to placebo, cariprazine 1.5 mg/d, cariprazine 3.0 mg/d, cariprazine 4.5 mg/d, or risperidone 4.0 mg/d (included for assay sensitivity) for 6 weeks of double-blind treatment. A 2-week safety period followed during which patients were cross-titrated and stabilized on appropriate medication as deemed necessary by the investigator. Cariprazine was initiated at 1.5 mg/d and increased by 1.5 mg until the target dose was reached (Day 2 or 3); risperidone was initiated at 2.0 mg/d and increased to 4.0 mg/d on Day 3.
Patients were hospitalized at screening and for at least 4 weeks of double-blind treatment. Starting on Day 28, discharge was allowed for patients with Clinical Global Impressions-Severity of Illness (CGI-S) (Guy, 1976b) scores of 3 (mildly ill) or less, no significant risk of suicide or violent behavior, and were ready for discharge in the opinion of the investigator; patients could be rehospitalized if their condition worsened.
Patients
Patients (18 to 60 years) met Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) (APA, 2000) criteria for schizophrenia (paranoid, disorganized, catatonic, or undifferentiated type) . Patients had the diagnosis for at least 1 year, current exacerbation less than 2 weeks' duration, and at least 1 psychotic episode requiring hospitalization/antipsychotic medication change/intervention during the preceding year. Patients experiencing a first episode of psychosis were excluded. Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987 (Kay et al., , 1991 total score between 80 and 120, a score ≥4 (moderate) on at least 2 of 4 PANSS positive symptoms (delusions, hallucinatory behavior, conceptual disorganization, suspiciousness/persecution), and CGI-S rating ≥4 were required. Body mass index (BMI) between 18 and 35 was also required.
Exclusion criteria included diagnosis of various DSM-IV-TR disorders (e.g., schizoaffective, schizophreniform, bipolar I and II); alcohol/ substance abuse/dependence (within 3 months) was prohibited. Patients with treatment-resistant schizophrenia (poor response to ≥2 antipsychotics of adequate dose and duration) or suicidal or homicidal attempt/intent (active or preceding 2 years) were excluded. Typical treatment-related, concomitant medication, and medical/physical exclusions were applied.
Concomitant medications
The use of psychotropic drugs (e.g., antipsychotics, neuroleptics, antidepressants, stimulants, mood stabilizers, sedatives/hypnotics/ anxiolytics, dopamine-releasing drugs or dopamine agonists) was not allowed. Zolpidem, zaleplon, chloral hydrate, or eszopiclone for insomnia were permitted. Diphenhydramine, benztropine, or propranolol was permitted as rescue medication for extrapyramidal (EPS) symptoms; lorazepam was permitted to control agitation, restlessness, irritability, and hostility.
Outcome assessments
PANSS and CGI-S were administered at screening, baseline, and at each visit (Weeks 1-6). Additionally, the 16-item Negative Symptom Assessment (NSA-16) (Axelrod et al., 1993 ) (baseline and Weeks 2, 4, and 6) and the Clinical Global Impressions-Improvement (CGI-I) (Guy, 1976b) (Weeks 1-6) were administered.
Treatment-emergent adverse events (TEAEs) were recorded at all visits. Additional safety assessments included physical examination, laboratory evaluations, vital signs, weight, and 12-lead ECG. EPS was monitored by the Abnormal Involuntary Movement Scale (AIMS) (Guy, 1976a) , Barnes Akathisia Rating Scale (BARS) (Barnes, 1989) , and Simpson-Angus Scale (SAS) (Simpson and Angus, 1970) at each visit.
Statistical analysis
The Safety Population comprised all randomized patients who received double-blind study medication. The Intent-to-Treat (ITT) Population comprised patients in the Safety Population with a postbaseline PANSS assessment; efficacy analyses were based on the ITT Population.
The percentage of patients who prematurely discontinued was compared between each active treatment group and placebo using Fisher's exact test. Between-group differences for demographic parameters and baseline characteristics were analyzed using 2-way analysis of variance (ANOVA) with treatment group and study center as factors for continuous variables; the Cochran-Mantel-Haenszel (CMH) test, controlling for study center, was used for categorical variables.
The primary efficacy parameter was change from baseline to Week 6 in PANSS total score using the last observation carried forward (LOCF) approach to impute missing postbaseline values. Between-group comparisons were conducted using an analysis of covariance model (ANCOVA) with treatment group and study center as factors and baseline PANSS total score as a covariate. To control overall type I error rate, a sequential, stepwise, multiple-comparison procedure was used.
The average effect of cariprazine 3.0 mg and 4.5 mg versus placebo was tested, followed by comparison of the individual cariprazine 3.0-mg and 4.5-mg groups versus placebo, and then the 1.5-mg group versus placebo. Two sensitivity analyses based on observed cases (OC) were performed using an ANCOVA model and a mixedeffects model for repeated measures (MMRM). For MMRM, treatment group, study center, visit, and treatment group-by-visit interaction were fixed effects and baseline value and baseline-by-visit interaction were covariates. The secondary efficacy parameter, CGI-S change from baseline to Week 6, was analyzed using similar methods.
Additional efficacy parameters were change from baseline to Week 6 in NSA-16 total and Global Negative Symptom Rating, PANSS Positive and Negative subscale scores, CGI-I score, and PANSS response (≥30% improvement from baseline) at Week 6. Additional efficacy parameters were analyzed by ANCOVA, except PANSS responder analysis, which used a logistic regression model with treatment group and baseline PANSS total score as explanatory variables.
Treatment-emergent EPS (parkinsonism) was defined as SAS score ≤ 3 at baseline and N3 at any postbaseline assessment; treatment-emergent akathisia was defined as BARS score ≤ 2 at baseline and N2 at any postbaseline assessment. Mean changes in EPS scales were analyzed using an ANCOVA model (without multiplicity adjustment). The Kaplan-Meier method was used to estimate the cumulative incidence rate of EPS-related AEs. All other safety parameters were analyzed using descriptive statistics only.
Risperidone and placebo were compared to assess assay sensitivity; no testing was done to compare active treatment groups. All statistical tests were 2-sided hypothesis tests performed at the 5% level of significance; all confidence intervals (CIs) were 2-sided 95% CIs. For all efficacy measures, statistical significance was defined as p values b 0.05. Primary and secondary efficacy measures were controlled for multiple comparisons; additional and by-visit efficacy outcomes were not controlled for multiple comparisons.
Results
Patient disposition and demographics
A total of 1011 patients were screened for eligibility and 732 patients were randomized to receive treatment. Approximately 38% of patients were enrolled in the United States, 22% in India, 22% in Russia, 16% in Ukraine, and 3% in Malaysia.
Approximately 64% of patients completed the study. The most frequent reasons for premature discontinuation are presented in Table 1 . Significantly more placebo patients than cariprazine or risperidone patients discontinued due to insufficient therapeutic response. Fewer cariprazine and risperidone patients compared with placebo patients discontinued because of AEs. AEs that led to discontinuation of 2 or more patients in any group were schizophrenia, psychotic disorder, and psychotic behavior, which occurred more frequently in placebo patients, and oromandibular dystonia, which occurred in 2 (1.4%) risperidone patients.
There were no significant differences in demographic characteristics among treatment groups (Table 2 ). Baseline disease characteristics were similar among groups except for a slight imbalance in previous suicide attempts.
Efficacy analyses
PANSS total score change from baseline to Week 6 (LOCF) was statistically significantly superior for each cariprazine group compared with placebo (Table 3) . Sensitivity analyses using MMRM and OC ANCOVA approaches demonstrated the robustness of cariprazine superiority. Statistically significant improvement was observed for cariprazine 3.0 and 4.5 mg/d versus placebo from Week 1 through Week 6 using LOCF and MMRM analysis (Fig. 1) ; cariprazine 1.5 mg/d demonstrated statistically significant improvement versus placebo from Week 2 through Week 6 (LOCF and MMRM). For the risperidone group, PANSS total score change at Week 6 was statistically significant versus placebo using LOCF, MMRM, and OC ANCOVA.
Mean baseline CGI-S scores approached 5, indicating that the study population was markedly ill. At Week 6, CGI-S scores were statistically significantly decreased in each cariprazine group and the risperidone group relative to placebo using both LOCF and MMRM approaches (Table 3) .
All 3 doses of cariprazine showed statistically significant improvement versus placebo on positive and negative symptoms as measured by the PANSS Positive and Negative subscales, and the NSA-16 (Table 3 ; Fig. 2 ). Relative to placebo, cariprazine groups also had statistically significantly lower CGI-I scores and greater rates of response (Table 3) . Risperidone also showed statistically significant advantage over placebo on secondary and additional efficacy measures.
Safety analyses
The mean duration of treatment was 30.5 days for placebo, 33.3 days, 33.9 days, and 34.0 days for cariprazine 1.5, 3.0, and 4.5 mg/d, respectively, and 35.0 days for risperidone.
Adverse events
An overall summary of AEs and commonly reported TEAEs during double-blind treatment is presented in Table 4 . The majority of the TEAEs were considered mild in intensity (approximately 70% in each group) and related to treatment. The most frequent TEAEs (≥5% and at least twice the rate of the placebo group) in the cariprazine groups were insomnia, extrapyramidal disorder, akathisia, sedation, nausea, dizziness, and constipation; no clear relationship between cariprazine dosages was observed. A total of 21 SAEs were reported in 19 patients during double-blind treatment. The only SAE reported in N 1 patient was psychotic behavior in the placebo group (3 patients). SAEs led to discontinuation in 13/19 patients (placebo, 5; cariprazine 1.5 mg/d, 4; cariprazine 4.5 mg/d, 1; risperidone, 3). There were no deaths reported during double-blind treatment; one patient died from cardio-respiratory arrest before taking any dose of study medication.
During the safety follow-up period, newly-emergent AEs (AEs not present before or worsening during the safety follow-up period) were observed in 12 (8%) placebo patients, 17 (12%), 16 (11%), and 14 (10%) cariprazine 1.5 mg, 3.0 mg, and 4.5 mg patients, respectively, and 9 (6%) risperidone patients. SAEs occurred in 17 patients during safety follow-up, with psychotic disorder (placebo, 2) and schizophrenia (cariprazine 3.0 mg/d, 2) being the only SAEs reported in N1 patient in any group.
Clinical laboratory parameters
Changes from baseline in alanine aminotransferase (ALT) levels were higher in the active treatment groups versus placebo (mean Mean changes from baseline in most metabolic parameters were small and similar between groups ( No increase in mean prolactin levels was observed in cariprazine or placebo groups; however, mean increase in prolactin levels was observed in risperidone-treated patients (Fig. 3) .
Vital sign evaluations
Mean changes in body weight and waist circumference were small and generally similar among groups (Table 5) . A higher percentage of patients in each cariprazine group relative to placebo had PCS increases in body weight (≥7% increase); no relationship to dosage was apparent (Table 5) . Risperidone was associated with the highest incidence of PCS weight gain. Mean changes in blood pressure and pulse were small and similar among groups (Table 5 ).
Electrocardiography
Mean changes in ventricular heart rate were slightly higher with cariprazine 4.5 mg/d (4.3 bpm) compared with placebo (0.3 bpm). Risperidone-treated patients had greater mean increase in QTcB and QTcF intervals (QTcB, +5.8 ms; QTcF, +5.1 ms) relative to patients treated with cariprazine 1.5 mg/d (QTcB, − 0.9 ms; QTcF, − 1.2 ms), cariprazine 3.0 mg/d (QTcB, − 3.4 ms; QTcF, − 3.1 ms), cariprazine 4.5 mg/d (QTcB, + 2.1 ms; QTcF: − 1.6 ms) and placebo-treated patients (QTcB, −1.1 ms; QTcF, −1.4 ms). No PCS postbaseline QTc prolongation (QTcB or QTcF N 500 ms) was reported.
Extrapyramidal symptoms
The cumulative incidence rate of all EPS-related TEAEs was higher for risperidone than for the other treatment groups (Fig. 4 ). There were no significant differences among groups on the BARS and SAS; a slightly greater increase in the mean AIMS score was observed with cariprazine 1.5 mg/d (+0.2) relative to placebo (−0.1), but no apparent dose relationship was observed (− 0.1 for cariprazine 3.0 and 4.5 mg/d). Relative to placebo, greater percentages of cariprazine and risperidone patients had treatment-emergent EPS (parkinsonism) and akathisia ( 
Discussion
Cariprazine 1.5 mg/d, 3.0 mg/d, and 4.5 mg/d showed significant improvement relative to placebo on the primary and secondary efficacy parameters, change from baseline in PANSS total and CGI-S, respectively. Cariprazine also demonstrated significant improvement versus placebo on the positive and negative symptoms of schizophrenia (assessed by PANSS Positive, PANSS Negative, and NSA-16 scores). Cariprazine was significantly superior to placebo on all other additional efficacy parameters as well.
In this cariprazine dose-finding study, dosages were selected based on prior pharmacokinetic (Ereshefsky et al., 2008) , PET receptor occupancy (Potkin et al., 2009) , and double-blind, placebo-controlled, flexible high-(6 to 12 mg/d) and low-(1.5-4.5 mg/d) dose, proof-ofconcept studies in patients with schizophrenia (Litman et al., 2008) . Based on the results of these preliminary studies, relatively low cariprazine doses were chosen to evaluate efficacy in the present study.
While significant improvement versus placebo was observed for the lowest cariprazine dose (1.5 mg/d) tested, greater treatment effects were observed with higher doses (3.0 mg/d and 4.5 mg/d); Baseline, mean ± SEM 55.9 ± 0.9 55.2 ± 1.0 56.0 ± 1.0 54.9 ± 0.9 55.5 ± 1.1 Change at Week 6, LSM ± SEM LOCF −3.8 ± 0.8 −7.7 ± 0.8 −8.3 ± 0.8 −9.3 ± 0.8 −9.6 ± 0.8 MMRM −5.6 ± 0.9 −9.7 ± 0.9 −9.6 ± 0.9 −10.5 ± 0.9 −11.1 ± 0.9 LSMD (95% CI) LOCF -−3.9 (−6.1, −1.7) ⁎⁎⁎ in contrast, tolerability did not appear to be dose related suggesting that higher doses of cariprazine may result in additional efficacy without compromising tolerability. Risperidone, the active comparator, also demonstrated significant improvement relative to placebo on all measures, demonstrating assay sensitivity and validating the study. The study was not designed to detect differences between cariprazine and risperidone; mean changes from baseline were larger in the risperidone group than for the cariprazine or placebo groups on many parameters.
Weight gain, glucose dysregulation, and lipid abnormalities are commonly associated with atypical antipsychotic treatments and are likely contributors to increased cardiovascular risk factors Daumit et al., 2008) . In this study, cariprazine potentially showed a more favorable weight gain profile than risperidone. Changes in metabolic (cholesterol, glucose, and triglycerides) parameters were small and similar among placebo and cariprazine groups. Risperidone, but not cariprazine, was associated with prolactin elevation. PCS changes in ECG parameters were not seen in either cariprazine or risperidone groups.
Greater percentages of both cariprazine and risperidone patients had treatment-emergent EPS (parkinsonism) and akathisia relative to placebo. The cumulative incidence curve suggested that risperidone-treated patients experienced more EPS-related TEAEs than cariprazine-treated patients during the course of study.
This study was limited by its short treatment duration and fixeddose design and lower dose range (from 1.5 to 4.5 mg/day). In realworld clinical practice, clinicians adjust patient dosage based on response, tolerability, and severity of illness.
Cariprazine is a new antipsychotic candidate with high affinity and potent partial agonist activity at both D 3 and D 2 receptors with preferential binding to D 3 receptors. Pharmacologically, it is most similar to the currently available antipsychotic aripiprazole, which also functions as a D 2 partial agonist. Compared with aripiprazole, cariprazine has higher affinity to D 3 and D 2 receptors and shows higher potency in in vitro functional assays and rodent behavioral models predictive of antipsychotic-like activity (Kiss et al., 2010; Gyertyán et al., 2011) . Additionally, cariprazine but not aripiprazole showed high occupancy of both D 3 and D 2 receptors in vivo (Gyertyán et al., 2011) . Further research is warranted to compare the clinical efficacy, safety, and tolerability of cariprazine with aripiprazole and other atypical antipsychotics (Zukin et al., 2012; Lieberman et al., 2013) . This 6-week trial supported the efficacy and safety of cariprazine in patients with acute exacerbation of schizophrenia. Given its unique pharmacological profile and positive past and present trial results, cariprazine may be an important new option for the treatment of schizophrenia.
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Proportion of patients with potentially clinically significant weight gain, n/N (%) ALT, alanine aminotransferase; AST, aspartate aminotransferase; AP, alkaline phosphatase; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; n, number of patients with a nonmissing baseline and at least one PCS postbaseline value during double-blind treatment, N, number of patients with a nonmissing baseline and at least one nonmissing postbaseline value during double-blind treatment; PCS, potentially clinically significant. a The BMI categories of 18.5 to b25 kg/m 2 , 25 to b30 kg/m 2 , and ≥30 kg/m 2 represent normal, overweight and obese categories, respectively. Patients with BMI b18.5 are considered underweight and were not included in this analysis (n = 24); only 1 patient from the underweight category had a 7% increase in weight (risperidone group). Fig. 4 . Cumulative incidence rate of all EPS-related adverse events. Kaplan-Meier plot representing cumulative incidence rates of EPS-related adverse events by time following first dose. EPS-related adverse events were akathisia, akinesia, bradykinesia, cogwheel rigidity, dyskinesia, dystonia, extrapyramidal disorder, oromandibular dystonia, parkinsonism, muscle rigidity, tardive dyskinesia, and tremor. EPS, extrapyramidal symptoms. 
